Eli Lilly and Company (LLY)

[TREND1]

biotech_researcher Tuesday, 10/28/14 05:20:17 PM

Quote:SNY/NVO/LLY—More on the competitive landscape in diabetes:

http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&ved=0CCQQFjAA&url=http%3A%2F%2Fblogs.wsj.com%2Fpharmalot%2F2014%2F10%2F28%2Fsanofi-diabetes-outlook-signals-an-undisciplined-price-war-may-erupt%2F&ei=-cBaVO7iJMyyoQT30YGoDQ&usg=AFQjCNHQD878MVZWf9c-44r6rnplMW862w&bvm=bv.78677474,d.cGU&cad=rjt




"In fact, the U.S. payer market is consolidating. Glaxo, as Moneybeat notes, estimates that the 10 largest commercial plans now control 86% of the marketplace, creating more visibility on contracting strategies and pricing. “I think you have a general shift in power toward the purchaser,” Glaxo chief executive Andrew Witty told analysts last week. Glaxo, for instance, is struggling to successfully launch its new Aroro respiratory treatment."